Abstract
Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan.
Lingua originale | English |
---|---|
pagine (da-a) | 1349-1352 |
Numero di pagine | 4 |
Rivista | Clinical Case Reports |
Volume | 8 |
Stato di pubblicazione | Published - 2020 |
All Science Journal Classification (ASJC) codes
- ???subjectarea.asjc.2700.2700???